嗪并[2,1-c][1,4]苯并恶嗪,1,2,3,4,4一个-1,5-六氢-(9CL) | 167024-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 嗪并[2,1-c][1,4]苯并恶嗪,1,2,3,4,4一个-1,5-六氢-(9CL)
• 中文别名: 哌啶正离子,4-(5H-二苯并[a,d]环庚烯-5-亚基)-1,1-二甲基-,碘化(1:1)
• 英文名称: 1,2,3,4,4a,5-hexahydro-1H-pyrazino[2,1-c][1,4]benzoxazine
• 英文别名: 1,2,3,4,4a,5-hexahydro-benzo[b]pyrazino[1,2-d][1,4]oxazine；2,3,4,4a,5,6-Hexahydro-1H-pyrazino<2,1-c>1,4-benzoxazin；1,2,3,4,4A,5-Hexahydropyrazino[2,1-C][1,4]benzoxazine
• CAS: 167024-14-8
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: JZKFDTSLBOMGLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  337.7±41.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氯-4'-氟苯丁酮 、 嗪并[2,1-c][1,4]苯并恶嗪,1,2,3,4,4一个-1,5-六氢-(9CL) 在 sodium carbonate 、 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 48.0h， 生成 1-(4-fluoro-phenyl)-4-(1,2,4a,5-tetrahydro-4H-benzo[b]pyrazino[1,2-d][1,4]oxazin-3-yl)-butan-1-one
  参考文献：
  名称：

  Gupta,S.P. et al., Indian Journal of Chemistry, 1975, vol. 13, p. 462 - 467

  摘要：

  DOI：
• 作为产物：
  描述：

  C-(3,4-二氢-2H-苯并[1,4]嗪-3-基)-甲胺 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 48.0h， 生成 嗪并[2,1-c][1,4]苯并恶嗪,1,2,3,4,4一个-1,5-六氢-(9CL)
  参考文献：
  名称：

  Gupta,S.P. et al., Indian Journal of Chemistry, 1975, vol. 13, p. 462 - 467

  摘要：

  DOI：

文献信息

• [EN] TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS<br/>[FR] COMPOSES TRICYCLIQUES ET LEUR UTILISATION COMME ANTAGONISTES DU MGLUR1
  申请人：SCHERING CORP

  公开号：WO2006002051A1

  公开（公告）日：2006-01-05

  In its many embodiments, the present invention provides tricyclic compounds of Formula (I) (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

  在其多种实施方式中，本发明提供了式(I)的三环化合物（其中J1-J4，X和R1-R5如本文所定义），作为代谢型谷氨酸受体（mGluR）拮抗剂，特别是选择性代谢型谷氨酸受体1拮抗剂，含有该化合物的制药组合物，以及使用该化合物和组合物治疗与代谢型谷氨酸受体（例如mGluR1）相关的疾病的治疗方法，如疼痛，偏头痛，焦虑，尿失禁和神经退行性疾病，例如阿尔茨海默病。
• [EN] PYRROLO-PYRIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRROLO-PYRIDINE
  申请人：MERCK SHARP & DOHME LIMITED

  公开号：WO1994020497A1

  公开（公告）日：1994-09-15

  (EN) A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.(FR) Classe de dérivés de pyrrolo[2,3-b]pyridine substitués en position 3 par une fraction pipérazinylméthyle. Lesdits dérivés sont des antagonistes de sous-types du récepteur de dopamine dans le cerveau, et présentent une affinité sélective pour le sous-type du récepteur D4 de dopamine plus que pour les autres sous-types du récepteur de dopamine, ce qui les rend utilisables dans le traitement et/ou la prophylaxie des troubles psychotiques tels que la schizophrénie, tout en présentant moins d'effets secondaires que ceux associés aux médicaments neuroleptiques classiques.

  一种以3位取代的哌嗪基甲基为侧链的吡咯并[2,3-b]嘧啶衍生物，是大脑中多巴胺受体亚型的选择性拮抗剂，尤其对多巴胺D4受体亚型具有较高的亲和力，因而能有效治疗或预防如精神分裂症等精神病性疾病，并表现出比传统神经阻滞药物更少的副作用。
• [EN] CONDENSED TRICYCLIC COMPOUND USED AS KINASE INHIBITOR<br/>[FR] COMPOSÉ TRICYCLIQUE CONDENSÉ UTILISÉ EN TANT QU'INHIBITEUR DE KINASE<br/>[ZH] 作为激酶抑制剂的稠合三环化合物
  申请人：HANGZHOU INNOGATE PHARMA CO LTD

  公开号：WO2020188467A1

  公开（公告）日：2020-09-24

  一类含有三环杂芳基化合物。具体地，提供了如下式(I)所示结构的化合物、含有式(I)化合物的药物组合物及所述化合物，以及这些化合物的同位素衍生物，手性异构体，变构体，不同的盐，前药，制剂等等。式(I)化合物能够有效抑制蛋白激酶（包括EGFR、EGFR(C797S)、 ALK和HPK1等），从而起到治疗各种肿瘤的作用。
• New Pyrimido[5,4-<i>b</i>]indoles as Ligands for α₁-Adrenoceptor Subtypes
  作者：Giuseppe Romeo、Luisa Materia、Fabrizio Manetti、Alfredo Cagnotto、Tiziana Mennini、Ferdinando Nicoletti、Maurizio Botta、Filippo Russo、Kenneth P. Minneman

  DOI：10.1021/jm0307741

  日期：2003.7.1

  A new series of compounds were designed as structural analogues of the alpha(1)-AR ligand RN5 (4), characterized by a tricyclic 5H-pyrimido[5,4-b]indole-(1H,3H)2,4-dione system connected through an alkyl. chain to a phenylpiperazine (PP) moiety. These compounds were synthesized and tested in binding assays on human alpha(1A)-AR, alpha(1B)-AR, and alpha(1D)-AR subtypes expressed in HEK293 cells. Several structural modifications were performed on the PP moiety, the tricyclic system, and the connecting alkyl chain. Many of the new molecules showed a preferential affinity for the alpha(1D)-AR subtype. Some compounds, including 39 and 40, displayed substantial alpha(1D)-AR selectivity with respect to alpha(1A)-AR, alpha(1B)-AR, serotonergic 5-HT1A, 5-HT1B, 5-HT2A, and dopaminergic D-1 and D-2 receptors. Two conformationally rigid analogues of 4, useful for studying the architecture of the receptor/ligand complex, were also prepared and tested. A subset of the new compounds was then used to evolve a preliminary pharmacophore model for alpha(1D)-AR antagonists, based on a more generalized model we had developed for alpha(1)-AR antagonists. This new model rationalized the relationships between structural properties and biological data of the pyrimido[5,4-b]indole compounds, as well as other compounds.
• Hindered rotation congeners of mazapertine: High affinity ligands for the 5-HT1A receptor
  作者：Ellen W. Baxter、Allen B. Reitz

  DOI：10.1016/s0960-894x(97)00074-7

  日期：1997.1

  Hindered rotation analogs of the antipsychotic mazapertine (1) were prepared. These compounds exhibited high affinity for the 5-HT1A receptor, but not for other serotonin or dopamine receptors. The related beta-carboline structures were also synthesized and were found to be potent 5-HT1A ligands. (C) 1997 Elsevier Science Ltd.